试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
编号:NCT03699956登记状态:提前终止企业 / 申办者:EpicentRx, Inc.
药物 / 成分:RRx-001 + eLOOP Device、Cisplatin/carboplatin plus etoposide
登记的停止原因(原文):RRx-001 will be studied under a new global, phase 3 clinical trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.
编号:NCT04126031登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3、Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
登记的停止原因(原文):Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
TXA in Anticoagulated Patients Study
编号:NCT04560010登记状态:提前终止企业 / 申办者:NYU Langone Health
药物 / 成分:Tranexamic Acid Injection (TXA)
登记的停止原因(原文):Enrollment rate was slower than anticipated
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
编号:NCT04899921登记状态:提前终止企业 / 申办者:Dana-Farber Cancer Institute
药物 / 成分:Ipilimumab、Nivolumab、Troriluzole、Placebo
登记的停止原因(原文):Due to poor enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
编号:NCT05125068登记状态:提前终止企业 / 申办者:Eledon Pharmaceuticals
药物 / 成分:AT-1501
登记的停止原因(原文):An administrative decision was made to terminate the AT-1501-N205 study. This voluntary business-related decision was not related to the safety of tegoprubart (AT-1501). Available safety data demonstrated tegoprubart to be safe and well tolerated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
A Study Explore JS001+JS002 in Patients With Advanced Cancer
编号:NCT05128539登记状态:提前终止企业 / 申办者:Shanghai Junshi Bioscience Co., Ltd.
药物 / 成分:JS001(Toripalimab)+JS002
登记的停止原因(原文):The regimen of JS002 75\~300mg Q3W has been completed, and the combination therapy is well tolerated and safe. However, considering that the efficacy did not reach the preset, it is recommended to terminate the trial in advance.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-26
Open-label Extension Study of ADP101
编号:NCT05243719登记状态:提前终止企业 / 申办者:Alladapt Immunotherapeutics, Inc.
药物 / 成分:ADP101
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-25
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
编号:NCT02231710登记状态:提前终止企业 / 申办者:Bellicum Pharmaceuticals
药物 / 成分:BPX-501 and Rimiducid
登记的停止原因(原文):due to lack of enrollment and changes to the sponsor development portfolio
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-25
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
编号:NCT03361800登记状态:提前终止企业 / 申办者:UNC Lineberger Comprehensive Cancer Center
药物 / 成分:Entinostat
登记的停止原因(原文):Funding withdrawn.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-25
Mouth Rinses for Inactivation of COVID-19
编号:NCT04584684登记状态:提前终止企业 / 申办者:University of North Carolina, Chapel Hill
药物 / 成分:0.9% w/v NaCL Saline、1.5% w/v Hydrogen Peroxide、0.12% Chlorohexidine Gluconate、27% Ethanol plus essential oils
登记的停止原因(原文):The team decided to terminate the trial in order to start a new trial, unrelated to safety reasons
查看官方原始记录 ↗